Joachim H. Ix

Joachim H. Ix

Auto-generated profile, based on publicly available information

Joachim H. Ix

Division of Nephrology-Hypertension, Department of Medicine and

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2010 in Annals of Internal Medicine
Verified
Journal Article
Open access
BPBenjamin D. Parker
Benjamin D. Parker
Leon SchurgersLeon Schurgers
Leon Schurgers
LSLeon J. Schurgers
Leon J. Schurgers
VBVincent M. Brandenburg
Vincent M. Brandenburg
RCRobert H. Christenson
Robert H. Christenson
JIJoachim H. Ix
Joachim H. Ix
Fibroblast growth factor 23 (FGF23), uncarboxylated matrix Gla protein (ucMGP), and fetuin-A are regulators of mineral metabolism and inhibitors of vascular calcification. These factors have been a... Background: Fibroblast growth factor 23 (FGF23), uncarboxylated matrix Gla protein (ucMGP), and fetuin-A are regulators of mineral metabolism and inhibitors of vascular calcification. Whether circu...

1 July 2012 in JACC
Verified
Journal Article
Closed access
JIJoachim H. Ix
Joachim H. Ix
RKRonit Katz
Ronit Katz
BKBryan R. Kestenbaum
Bryan R. Kestenbaum
IBIan H. de Boer
Ian H. de Boer
MCMichel Chonchol
Michel Chonchol
MSMichael G. Shlipak
Michael G. Shlipak

9 July 2008 in JAMA
Verified
Journal Article
Closed access
JIJoachim H. Ix
Joachim H. Ix
Fetuin-A is a hepatic secretory protein that binds the insulin receptor and inhibits insulin action in vitro. In prior cross-sectional studies in humans, higher fetuin-A levels were associated with insulin resistance. However, the longitudinal association of fetuin-A with incident type 2 diabetes mellitus is unknown. To determine whether fetuin-A levels are associated with incident diabetes in older persons. Observational study among 3075 well-functioning persons aged 70 to 79 years. In this case-cohort study, we retrospectively measured fetuin-A levels in baseline serum among 406 randomly selected participants without prevalent diabetes, and all participants who developed incident diabetes mellitus during a 6-year follow-up (to August 31, 2005). Incident diabetes mellitus. Incident diabetes developed in 135 participants (10.1 cases/1000 person-years). Participants with fetuin-A levels within the highest tertile (> 0.97 g/L) had an increased risk of incident diabetes (13.3 cases/1000 person-years) compared with participants in the lowest tertile (< or = 0.76 g/L) (6.5 cases/1000 person-years) in models adjusted for age, sex, race, waist circumference, body weight, physical activity, blood pressure level, fasting glucose level, high-density lipoprotein cholesterol concentration, triglyceride concentration, and C-reactive protein level (adjusted hazard ratio, 2.41; 95% confidence interval, 1.28-4.53; P = .007). The association was not affected by adipocytokine levels but was moderately attenuated by adjustment for visceral adiposity (adjusted hazard ratio of highest vs lowest tertile 1.72; 95% confidence interval, 0.98-3.05; P = .06). Among well-functioning older persons, serum fetuin-A is associated with incident diabetes, independent of other markers of insulin resistance.

1 October 2017 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
RMRakesh Malhotra
Rakesh Malhotra
HNHoang Anh Nguyen
Hoang Anh Nguyen
OBOscar Benavente
Oscar Benavente
MMMihriye Mete
Mihriye Mete
BHBarbara V. Howard
Barbara V. Howard
JIJoachim H. Ix
Joachim H. Ix
Chronic kidney disease (CKD) is a major public health problem, estimated to affect 26 million Americans and 200 million individuals worldwide.1,2 Persons with CKD are at high risk of cardiovascular disease (CVD), progression to end-stage renal disease (ESRD), and all-cause mortality.3 Hypertension is a well-known risk factor for CVD; therefore, optimal blood pressure (BP) control is a major clinical and public health priority.4,5 Over the past decade, several studies and clinical practice guidelines6-10 have addressed the optimal BP target in CKD populations, yet consensus remains elusive. Observational data have demonstrated U-shaped relationships between BP and mortality risk among those with CKD.11,12 Clinical trials testing different BP targets in CKD populations, including the Modification of Diet in Renal Disease (MDRD)13 and the African American Study of Kidney Disease and Hypertension (AASK),14 failed to demonstrate benefits of BP lowering for slowing down CKD progression and were underpowered to address CVD and mortality.

1 January 2011 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
JIJoachim H. Ix
Joachim H. Ix
CWChristina L. Wassel
Christina L. Wassel
LSLesley A. Stevens
Lesley A. Stevens
GBGerald J. Beck
Gerald J. Beck
MFMarc Froissart
Marc Froissart
ALAndrew S. Levey
Andrew S. Levey
Summary: Background and objectives: Creatinine excretion rate (CER) indicates timed urine collection accuracy. Although equations to estimate CER exist, their bias and precision are untested and none simultaneously include age, sex, race, and weight. Design, setting, participants, & measurements: Participants (n = 2466) from three kidney disease trials were randomly allocated into equation development (2/3) and internal validation (1/3) data sets. CER served as the dependent variable in linear regression to develop new equations. Their stability was assessed within the internal validation data set. Among 987 individuals from three additional studies the equations were externally validated and compared with existing equations. Results: Mean age was 46 years, 42% were women, and 9% were black. Age, sex, race, weight, and serum phosphorus improved model fit. Two equations were developed, with or without serum phosphorus. In external validation, the new equations showed little bias (mean difference [measured − estimated CER] −0.7% [95% confidence interval −2.5% to 1.0%] and 0.3% [95% confidence interval −2.6% to 3.1%], respectively) and moderate precision (estimated CER within 30% of measured CER among 79% [76% to 81%] and 81% [77% to 85%], respectively). Corresponding numbers within 15% were 51% [48% to 54%] and 54% [50% to 59%]). Compared with existing equations, the new equations had similar accuracy but showed less bias in individuals with high measured CER. Conclusions: CER can be estimated with commonly available variables with little bias and moderate precision, which may facilitate assessment of accuracy of timed urine collections.

1 March 2009 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
JIJoachim H. Ix
Joachim H. Ix
IBIan H. De Boer
Ian H. De Boer
CPCarmen A. Peralta
Carmen A. Peralta
KAKathryn L. Adeney
Kathryn L. Adeney
DDDaniel A. Duprez
Daniel A. Duprez
BKBryan R. Kestenbaum
Bryan R. Kestenbaum
Background and objectives: Higher phosphorus levels are associated with cardiovascular disease (CVD) events and mortality. Whether vascular stiffness may be responsible is unknown. Design, setting, participants, & measurements: This study examined the cross-sectional associations of serum phosphorus with ankle brachial index (ABI), pulse pressure, and large and small artery elasticity by radial artery waveform analysis among 1370 individuals (440 with moderate chronic kidney disease) who did not have clinical CVD and participated in the Multi-Ethnic Study of Atherosclerosis. Results: Fifty-nine (4%) individuals had high ABI (>1.30), a marker of peripheral arterial stiffness. Participants with phosphorus levels >4 mg/dl had greater than four-fold risk for high ABI compared with participants with phosphate levels <3 mg/dl (relative risk 4.6; 95% confidence interval 1.6 to 13.2; P = 0.01) after adjustment for demographics, traditional CVD risk factors, and kidney function. Higher phosphorus levels were also associated with greater pulse pressure and lesser large and small artery elasticity in unadjusted models, but these associations were attenuated after adjustment. Conclusions: Higher phosphorus levels are strongly associated with high ABI but not pulse pressure or large or small artery elasticity. If confirmed in future studies, then the association of higher phosphorus concentrations with CVD events may be partially mediated through peripheral arterial stiffness.